Table 4. ADT by type and the risk of subsequent hematologic disorders.
| Hematologic disorders | Anemia | Hematologic malignancy | ||||
|---|---|---|---|---|---|---|
| ADT exposure | Adjusted HR (95% CI) | P-value | Adjusted HR (95% CI) | P-value | Adjusted HR (95% CI) | P-value |
| RP | 1.00 (ref. group) | -- | 1.00 (ref. group) | -- | 1.00 (ref. group) | -- |
| GnRH agonists | 2.75 (2.13–3.53) | <0.001** | 2.82 (2.18–3.65) | <0.001** | 1.10 (0.35–3.46) | 0.866 |
| Oral antiandrogens only | 1.79 (1.45–2.22) | <0.001** | 1.80 (1.45–2.24) | <0.001** | 1.76 (0.86–3.60) | 0.124 |
| Estrogens only | 0.82 (0.20–3.31) | 0.774 | 0.86 (0.21–3.50) | 0.836 | NA | NA |
| Other combinations | 1.24 (0.96–1.61) | 0.104 | 1.25 (0.96–1.64) | 0.101 | 1.30 (0.52–3.26) | 0.578 |
Abbreviations: ADT, androgen deprivation therapy; RP, radical prostatectomy; GnRH, gonadotropin-releasing hormone; HR, hazard ratio; CI, confidence interval; NA, not applicable
*P <0.05
**P <0.001